Licensing, Acquisitions, and Other Arrangement- Acquisitions of Nimble Therapeutics, Inc. (Details) - Nimble Therapeutics - USD ($) $ in Millions |
3 Months Ended | |
|---|---|---|
Jun. 30, 2026 |
Jan. 23, 2025 |
|
| Collaborative and license agreements | ||
| Total consideration | $ 288 | |
| Upfront cash payment | $ 210 | |
| Contingent consideration | $ 78 | |
| Maximum future payments upon achievement of certain milestones | $ 130 |
| X | ||||||||||
- Definition Represents the maximum additional payment for research and early development of collaboration projects. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|